Vyleesi Cost in Georgia 2026: Cash Price, Insurance, Compounded Options

What Is Vyleesi and Who Is It For?

Vyleesi is the brand name for bremelanotide, a melanocortin receptor agonist approved by the FDA on June 21, 2019, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It works on MC1R and MC4R receptors in the central nervous system rather than on hormones or genital blood flow, making it mechanistically distinct from flibanserin (Addyi) and from all estrogen- or testosterone-based therapies. The drug is self-administered as a 1.75 mg subcutaneous injection to the abdomen or thigh approximately 45 minutes before anticipated sexual activity, no more than once in 24 hours and no more than once per eight-week period is not a stated limit. The label does cap monthly use at roughly eight injections.

HSDD is the most common female sexual dysfunction in the United States, affecting an estimated 10% of premenopausal women, though prevalence studies vary widely depending on diagnostic criteria. The condition is defined by persistently low sexual desire that causes marked distress or interpersonal difficulty and is not explained by a co-existing medical or psychiatric condition. Diagnostic criteria originate from DSM-5 and the International Society for the Study of Women's Sexual Health (ISSWSH) guidelines.

Georgia physicians, including those practicing via telehealth platforms, can legally prescribe Vyleesi because bremelanotide is not a federally scheduled controlled substance. A standard written prescription sent to a retail or compounding pharmacy is all that is required.

Vyleesi List Price in Georgia in 2026

The manufacturer list price for Vyleesi sits at approximately $1,200 per month in Georgia, a figure that has remained stable since the drug's launch. That price reflects a single carton containing four 1.75 mg auto-injectors. At that rate, annual spending without insurance or discount programs reaches roughly $14,400, which places Vyleesi in the same general cost tier as many specialty biologics.

Cash-pay prices at Georgia retail pharmacies in 2026 track very close to the list price. Unlike generic drugs, where pharmacy acquisition costs diverge sharply from the list price, brand-name specialty products like Vyleesi typically show minimal variation across CVS, Walgreens, Publix, and independent Atlanta-area pharmacies. GoodRx and similar aggregators may post slightly lower cash prices in the $950 to $1,150 range for a four-injector pack, but savings rarely exceed 10% to 15% off list without a manufacturer coupon layered on top.

For comparison, flibanserin (Addyi), the only other FDA-approved pharmacological treatment for HSDD, carries a cash price of approximately $800 to $1,000 per month for a 30-tablet supply, though it requires daily oral dosing rather than as-needed use. That distinction matters for some patients who prefer not to commit to a daily regimen.

The table below summarizes cost tiers a Georgia patient is likely to encounter in 2026:

| Access Pathway | Estimated Monthly Cost (Georgia, 2026) | |---|---| | Brand cash pay (retail) | $950 to $1,200 | | Commercial insurance with co-pay card | $0 to $100 (where covered) | | Palatin savings card (commercially insured only) | As low as $0 per month (subject to eligibility) | | Licensed 503A compounded bremelanotide | $120 to $160 | | Georgia Medicaid | Not covered |

Does Georgia Medicaid Cover Vyleesi?

Georgia Medicaid does not cover Vyleesi for hypoactive sexual desire disorder. The Georgia Department of Community Health Medicaid formulary excludes bremelanotide under its current preferred drug list, and no pathway for prior authorization approval exists for the HSDD indication at this time. This is consistent with the coverage posture of most state Medicaid programs nationally; very few have added Vyleesi to their formularies since approval.

The exclusion stems from two overlapping factors. First, Medicaid drug coverage decisions weigh cost-effectiveness heavily, and at a $1,200 monthly list price with a relatively modest effect size in the RECONNECT trials (discussed below), the drug has not cleared the cost-utility threshold that Georgia Medicaid sets. Second, HSDD is classified by some payers as a "lifestyle" condition, a categorization that sexual health advocates have challenged on the grounds that HSDD causes clinically meaningful distress and functional impairment.

Patients enrolled in Georgia Medicaid who want bremelanotide have two realistic options: self-pay for compounded bremelanotide (see the next section) or pursue non-pharmacological treatments such as cognitive behavioral therapy or mindfulness-based sex therapy, which some Medicaid mental health carve-outs may cover.

There is no federal mandate that Medicaid programs cover HSDD treatments. The Affordable Care Act's essential health benefits framework does not explicitly require coverage of female sexual dysfunction medications, and the FDA's 2019 approval of Vyleesi did not change that calculus.

Is Compounded Bremelanotide Legal in Georgia?

Compounded bremelanotide is legal in Georgia when dispensed by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber. Georgia follows federal 503A guidelines established under the Drug Quality and Security Act of 2013 and enforced by the FDA, and the Georgia State Board of Pharmacy requires compounding pharmacies to meet USP standards for sterile preparations.

The key legal distinction is between 503A pharmacies (patient-specific compounding, the dominant model in Georgia for bremelanotide) and 503B outsourcing facilities (bulk compounding for hospitals and clinics). Most telehealth platforms in Georgia that prescribe compounded bremelanotide work with 503A pharmacies, which legally compound the drug after receiving an individualized prescription. The pharmacy mixes the active pharmaceutical ingredient (API) into a sterile injectable formulation, typically a multi-dose vial at a concentration of 10 mg/mL.

At approximately $120 to $160 per month, compounded bremelanotide costs roughly 87% less than brand Vyleesi. That price gap is significant. A patient switching from brand to compounded saves between $1,000 and $1,080 per month, or $12,000 to $12,960 per year, which for many Georgian women without insurance coverage is the deciding factor.

Several caveats apply. Compounded products are not FDA-approved. They have not undergone the same manufacturing quality controls as Palatin's commercial product. Sterility, potency, and stability can vary between compounding pharmacies. Patients should verify that the pharmacy they use is licensed by the Georgia State Board of Pharmacy and, ideally, accredited by the Pharmacy Compounding Accreditation Board (PCAB). The FDA's guidance on compounding provides additional context on legal requirements.

What the Clinical Evidence Says About Bremelanotide

The key evidence for Vyleesi comes from the RECONNECT program, two identical Phase 3 randomized controlled trials published in Obstetrics and Gynecology in 2019. Across both trials (combined N=1,247 premenopausal women with acquired, generalized HSDD), bremelanotide produced statistically significant improvements in sexual desire and in sexually related personal distress compared with placebo at 24 weeks. Specifically, 24.5% of bremelanotide-treated women achieved a clinically meaningful decrease in distress (defined as a reduction of 1.2 or more points on the Female Sexual Distress Scale-Desire/Arousal/Orgasm) versus 17.0% in the placebo group (P<0.001).

The drug's effect size is real but modest. The authors noted: "Bremelanotide improved the number of satisfying sexual events and sexual desire while decreasing sexually related personal distress." That language reflects a genuine but not dramatic average benefit, which means patient selection matters. Women who respond tend to notice the effect within the first few uses; those who do not respond by the fourth or fifth injection may be unlikely to benefit.

Nausea is the most common adverse effect, occurring in approximately 40% of users in RECONNECT. Flushing, headache, and transient increases in blood pressure (mean increase of 2 mmHg systolic, lasting roughly 12 hours) were also reported. The transient blood pressure effect is why Palatin's label includes a contraindication for women with known cardiovascular disease or uncontrolled hypertension. Georgia prescribers should screen for these conditions before initiating therapy.

The FDA-approved prescribing information lists nausea (40.0%), flushing (20.3%), and headache (11.0%) as the most common adverse reactions occurring in at least 2% of treated patients and more frequently than placebo.

Commercial Insurance Coverage for Vyleesi in Georgia

Most large commercial insurance plans operating in Georgia, including BlueCross BlueShield of Georgia, United Healthcare, Cigna, and Aetna, have varied Vyleesi coverage depending on the specific plan and employer benefit design. Coverage is not uniform.

Where Vyleesi appears on formulary at all, it is typically placed on a specialty tier (Tier 4 or Tier 5), meaning patient cost-sharing can still run $300 to $600 per month before any savings program is applied. Prior authorization is nearly universal for those plans that do cover it; common PA requirements include documentation of an HSDD diagnosis by a licensed clinician, confirmation that the patient has tried at least one non-pharmacological treatment, and sometimes a mental health consultation note.

Georgia's state employee health plan (SHBP), which covers state workers and their dependents, follows the State Health Benefit Plan's preferred drug list. As of 2025, Vyleesi had not been added to SHBP's covered drug list.

Women covered by ACA marketplace plans in Georgia face the same variability. Bremelanotide is not among the drugs that ACA essential health benefits rules require plans to cover, so coverage is discretionary. Patients should call the member services number on their insurance card and specifically ask whether Vyleesi is on their drug formulary, what tier it is on, and what the prior authorization criteria are.

The Palatin Technologies Co-Pay Savings Card

Palatin Technologies, Vyleesi's manufacturer, offers a patient savings card for commercially insured patients that can reduce out-of-pocket cost to as low as $0 per month, subject to program terms, eligibility caps, and annual maximums. The savings card does not apply to patients covered by Medicare, Medicaid, or any federal or state government health program, which explicitly excludes Georgia Medicaid enrollees.

To use the card in Georgia, a patient must:

1. Obtain a valid Vyleesi prescription from a licensed Georgia prescriber or telehealth provider.
2. Fill the prescription at a participating retail pharmacy.
3. Present the savings card (downloadable from Palatin's official site or obtainable through the prescribing clinician's office) at the point of sale.

The program has historically covered up to $3,600 per year per patient, meaning roughly $300 per month in manufacturer-funded cost support. For a patient whose insurance plan places Vyleesi on a specialty tier at $400 to $500 per month, the savings card may bring the effective cost to $100 to $200 per month. Palatin's program terms change annually; patients should verify current limits directly with Palatin or through a specialty pharmacy. The FDA's drug approval page contains full prescribing and labeling information that pharmacies reference when processing these claims.

Getting Vyleesi via Telehealth in Georgia

Telehealth prescribing of Vyleesi is legal in Georgia. Because bremelanotide is not a controlled substance, prescribers do not need to conduct an in-person examination or register under the Ryan Haight Act before prescribing it remotely. A synchronous video consultation with a licensed Georgia physician or advanced practice provider is sufficient to establish the clinical relationship required under Georgia telehealth law.

Several national telehealth platforms operating in Georgia offer bremelanotide prescriptions, including services that specialize in women's sexual health and hormone-related conditions. A typical telehealth visit costs $50 to $150 for the initial consultation, with follow-up visits running $30 to $75 in most cases. Some platforms include the prescribing visit in a monthly membership fee.

The telehealth model also makes accessing compounded bremelanotide straightforward. The clinician writes a prescription electronically to a partnered 503A pharmacy, which ships the refrigerated injectable directly to the patient's Georgia address. Shipping typically runs two to four business days.

Women in Georgia's rural counties, where sexual health specialists are scarce or nonexistent, may find telehealth the most practical access route. The Georgia Telehealth Policy Center notes that telehealth use in the state expanded significantly following 2020 policy changes, with continued flexibility for non-controlled prescribing.

Clinical Considerations Before Starting Bremelanotide in Georgia

Before a Georgia prescriber issues a Vyleesi prescription, the clinical workup should rule out secondary causes of low sexual desire. Thyroid dysfunction, hyperprolactinemia, depression, relationship conflict, medication side effects (particularly SSRIs and oral contraceptives), and genitopelvic pain disorders can all suppress sexual desire and may respond better to targeted treatment than to bremelanotide.

The ISSWSH and the North American Menopause Society (NAMS) both recommend a biopsychosocial evaluation before initiating pharmacotherapy for HSDD. NAMS clinical guidelines state that treatment for sexual dysfunction should begin with education, communication strategies, and addressing relationship factors before pharmacological agents are considered.

Bremelanotide is contraindicated in women with:

• Known cardiovascular disease
• Uncontrolled hypertension (systolic BP above 165 mmHg or diastolic above 95 mmHg)
• High cardiovascular risk (as defined by a 10-year Framingham risk score above 20%)

Blood pressure should be measured before each injection given the drug's transient pressor effect. The prescribing label recommends checking BP 12 hours after the first dose to confirm it returns to baseline.

Drug interactions are limited but include the potential for slowed gastric absorption of oral medications when bremelanotide is used concurrently, which could theoretically reduce the effectiveness of oral contraceptives taken around the same time. Patients should separate bremelanotide injection from oral contraceptive dosing by at least one hour.

The Cheapest Way to Get Bremelanotide in Georgia

For most Georgia women without commercial insurance coverage, compounded bremelanotide from a licensed 503A pharmacy, obtained via a telehealth prescription, is the lowest-cost legal access pathway in 2026. Total monthly spend, including the cost of a telehealth visit amortized over three months, runs approximately $175 to $220 per month, compared with $950 to $1,200 for brand Vyleesi without insurance.

For commercially insured patients whose plan covers Vyleesi, layering the Palatin co-pay card on top of insurance can bring out-of-pocket costs to less than $100 per month or potentially zero. That makes brand Vyleesi financially competitive with the compounded alternative for this subset of patients, with the added assurance of FDA-regulated manufacturing.

Georgia patients who qualify for neither insurance coverage nor the manufacturer savings card face a stark choice: pay $1,200 per month cash for brand or $140 for compounded. Given the legal availability of compounded bremelanotide in Georgia and the absence of any formulary or savings-card pathway for most uninsured women, the compounded route will likely represent the dominant prescribing pattern among telehealth platforms serving Georgia in 2026.